Efficacy of Ganitumab (AMG 479), Alone and in Combination With Rapamycin, in Ewing's and Osteogenic Sarcoma Models.

Beltran, P.J., Chung, Y.A., Moody, G., Mitchell, P., Cajulis, E., Vonderfecht, S., Kendall, R., Radinsky, R., Calzone, F.J.
Journal   Pharmacol Exp Ther.
Species  
Analytes Measured   Akt , IGF-1R , IR , IRS-1 , p70S6K
Matrix Tested   Tumor xenograft lysates
Year   2011
Volume  
Page Numbers  
Application   Phosphoproteins
Abstract
Ewing's and osteogenic sarcoma are two of the leading causes of cancer deaths in children and adolescents. Recent data suggest that sarcomas may depend on the insulin-like growth factor type 1 (IGF-1) receptor (IGF1R) and/or the insulin receptor (INSR) to drive tumor growth, survival, and resistance to mammalian target of rapamycin complex 1 (mTORC1) inhibitors. We evaluated the therapeutic value of ganitumab (AMG 479; C(6472)H(10028)N(1728)O(2020)S(42)), an anti-IGF1R, fully human monoclonal antibody, alone and in combination with rapamycin (mTORC1 inhibitor) in Ewing's (SK-ES-1 and A673) and osteogenic (SJSA-1) sarcoma models. IGF1R was activated by IGF-1 but not by insulin in each sarcoma model. INSR was also activated by IGF-1 in the SJSA-1 and SK-ES-1 models, but not in the A673 model where insulin was the preferred INSR ligand. Ganitumab significantly inhibited the growth of SJSA-1 and SK-ES-1 xenografts; inhibition was associated with decreased IGF1R and Akt phosphorylation, reduced total IGF1R and bromodeoxyuridine detection, and increased caspase-3 expression. Ganitumab inhibited rapamycin-induced IGF1R, Akt, and glycogen synthase kinase-3β hyperphosphorylation in each sarcoma model. However, ganitumab in combination with rapamycin also resulted in a marked increase in INSR expression and activity in the SJSA-1 and A673 models. The in vivo efficacy of ganitumab in the two ganitumab-sensitive models (SJSA-1 and SK-ES-1) was significantly enhanced in combination with rapamycin. Our results support studying ganitumab in combination with mTORC1 inhibitors for the treatment of sarcomas and suggest that INSR signaling is an important mechanism of resistance to IGF1R blockade.

View Publications

Related Products

R-PLEX Human IRS-1 Antibody Set
IRS-1 | Human
Phospho-Akt (Ser473) Antibody
Akt
Total Akt Antibody Bulk Product
Akt
Phospho-Akt (Ser473) Kit
Akt | Human, Mouse, Rat, Non-human primate
Singleplex
Total Akt Kit
Akt | Human, Mouse, Rat, Non-human primate
Singleplex
Akt Control Pack 1
Akt
Akt Signaling Whole Cell Lysate Kit
Akt, GSK-3β, p70S6K | Human, Mouse, Rat
Multiplex
Akt Signaling Panel II Whole Cell Lysate Kit
Akt, GSK-3β, p70S6K, S6RP | Human, Mouse, Rat
Multiplex
Insulin Signaling Panel (Total Protein) Kit
IGF-1R, IR, IRS-1 | Human
Multiplex
Insulin Signaling Panel (Phospho Protein) Kit
IGF-1R, IgG, IR, IRS-1 | Human
Multiplex
Phospho-IRS-1 (Ser312) Whole Cell Lysate Kit
IRS-1 | Human
Singleplex
Phospho(Ser473)/Total Akt Whole Cell Lysate Kit
Akt | Human, Mouse, Rat
Multiplex
Phospho-p70S6K (Thr421/Ser424) Whole Cell Lysate Kit
p70S6K | Human, Mouse
Singleplex
Phospho-p70S6K (Thr389) Whole Cell Lysate Kit
p70S6K | Human, Mouse, Rat
Singleplex
Total p70S6K Whole Cell Lysate Kit
p70S6K | Human, Mouse, Rat
Singleplex
Akt Signaling (Total Protein) Whole Cell Lysate Kit
Akt, GSK-3β, p70S6K | Human, Mouse, Rat
Multiplex
Phospho (Thr421/Ser424)/Total p70S6K Whole Cell Lysate Kit 5
p70S6K | Human, Mouse, Rat
Multiplex
Phospho-Akt (Thr308) Whole Cell Lysate Kit
Akt | Human, Mouse
Singleplex
Browse Our Products

By Analytes
By Applications
Search
Customer Service/Orders


Scientific/Technical Support


Instrument Support


Company Headquarters